Yoshihara Kyoko, Orihara Yoshiyuki, Hoshiyama Tokiko, Tamaki Hiroya, Sunayama Isamu, Matsuda Ikuo, Nishikawa Akinori, Kumamoto Tomoko, Samori Mami, Utsunomiya Nobuto, Min Kyung-Duk, Asakura Masanori, Hirota Seiichi, Ishihara Masaharu, Higasa Satoshi, Yoshihara Satoshi
Department of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Department of Cardiovascular and Renal Medicine, Hyogo Medical University Hospital, Hyogo, Japan.
Leuk Res Rep. 2022 Jul 14;18:100338. doi: 10.1016/j.lrr.2022.100338. eCollection 2022.
Although cardiac dysfunction after chimeric antigen receptor (CAR) T-cell therapy has been increasingly reported, the underlying dynamics and pathogenesis are not well documented. Herein, we describe the clinical presentation and treatment for two patients who developed severe acute heart failure after CAR T-cell therapy. Both cases shared several common characteristics, including the bone marrow involvement at the time of CAR T-cell therapy and early onset of cytokine release syndrome (CRS) with fever developing on the day of CAR T-cell infusion. Patients with early onset and/or severe CRS should be carefully monitored for the possibility of heart failure.
尽管嵌合抗原受体（CAR）T细胞治疗后心脏功能障碍的报道越来越多，但其潜在机制和发病机制尚未得到充分记录。在此，我们描述了两名接受CAR T细胞治疗后发生严重急性心力衰竭患者的临床表现和治疗情况。这两个病例有几个共同特征，包括CAR T细胞治疗时骨髓受累以及细胞因子释放综合征（CRS）早期发作，在CAR T细胞输注当天出现发热。对于早期发作和/或严重CRS的患者，应密切监测心力衰竭的可能性。
